104 related articles for article (PubMed ID: 29127747)
21. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
Buturovic BA; Ristic LB; Narancic AM
Med Arch; 2014 Oct; 68(5):313-6. PubMed ID: 25568561
[TBL] [Abstract][Full Text] [Related]
22. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Lam S; Saad M
Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
[TBL] [Abstract][Full Text] [Related]
23. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
24. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
25. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
28. In support of an early polypharmacy approach to the treatment of type 2 diabetes.
Wright EE; Stonehouse AH; Cuddihy RM
Diabetes Obes Metab; 2010 Nov; 12(11):929-40. PubMed ID: 20880339
[TBL] [Abstract][Full Text] [Related]
29. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
30. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2015 Sep; 14():129. PubMed ID: 26415691
[TBL] [Abstract][Full Text] [Related]
31. Addition of incretin therapy to metformin in type 2 diabetes.
Scheen AJ; Radermecker RP
Lancet; 2010 Apr; 375(9724):1410-2. PubMed ID: 20417840
[No Abstract] [Full Text] [Related]
32. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
Skandalis K; Spirova M; Gaitanis G; Tsartsarakis A; Bassukas ID
J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):249-53. PubMed ID: 21466592
[TBL] [Abstract][Full Text] [Related]
34. PURLs: Need an add-on to metformin? Consider this.
Wyncott D; Lyon C; Mounsey A
J Fam Pract; 2017 Jan; 66(1):42-44. PubMed ID: 28188318
[TBL] [Abstract][Full Text] [Related]
35. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
36. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Overbeek JA; Heintjes EM; Prieto-Alhambra D; Blin P; Lassalle R; Hall GC; Lapi F; Bianchini E; Hammar N; Bezemer ID; Herings RMC
Clin Ther; 2017 Apr; 39(4):759-770. PubMed ID: 28342563
[TBL] [Abstract][Full Text] [Related]
37. Metformin and other antidiabetic agents in renal failure patients.
Lalau JD; Arnouts P; Sharif A; De Broe ME
Kidney Int; 2015 Feb; 87(2):308-22. PubMed ID: 24599253
[TBL] [Abstract][Full Text] [Related]
38. [A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)].
Martinka E; Uličiansky V; Mokáň M; Tkáč I; Galajda P; Dókušová S; Schroner Z
Vnitr Lek; 2018; 64(4):405-426. PubMed ID: 29791176
[TBL] [Abstract][Full Text] [Related]
39. [A revolution in the management of type 2 diabetes : antidiabetic agents providing a cardiovascular and renal protection independently of glucose control !].
Scheen AJ; Paquot N
Rev Med Liege; 2020 May; 75(5-6):392-398. PubMed ID: 32496686
[TBL] [Abstract][Full Text] [Related]
40. [The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003-2013 and came closer to the population average].
Brož J; Honěk P; Dušek L; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S14-20. PubMed ID: 26652960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
